Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.
Ixabepilone is a novel microtubule-stabilising agent used as monotherapy or in combination with capecitabine to treat taxane- and anthracycline-refractory breast cancer. We report the case of a patient who experienced an unusual motor neuropathy after the first cycle. This is a very uncommon secondary effect, but it must be taken into account as a possible complication of treatment with ixabepilone.
Bosch-Barrera
Joaquim
J
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain. jbosch@unav.es
Espinós
Jaime
J
Gómez-Ibáñez
Asier
A
Gállego Pérez-Larraya
Jaime
J
Iriarte
Jorge
J
D001369:Axons / Q000378:metabolism*; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D034261:Epothilones / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008870:Microtubules / Q000378:metabolism; D008875:Middle Aged; D009475:Neurons, Afferent / Q000187:drug effects* / Q000378:metabolism*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000009:adverse effects
D034261:Epothilones; D050257:Tubulin Modulators; C430592:ixabepilone